SCHEMBL4086221

SCHEMBL4086221

CC(=O)Nc1ccc(CC(N)=O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.59
AOC3 Q16853 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
HTT P42858 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
TSHR P16473 2/20 0.54
KMT2A Q03164 3/20 0.53
ALDH1A1 P00352 3/20 0.53
CA2 P00918 2/20 0.53
MEN1 O00255 2/20 0.53
CA12 O43570 1/20 0.53
BRD4 O60885 1/20 0.53
NR1I2 O75469 1/20 0.53
CA1 P00915 1/20 0.53
MB P02144 1/20 0.53
CYP1A1 P04798 1/20 0.53
CA3 P07451 1/20 0.53
CYP3A4 P08684 1/20 0.53
MAPT P10636 1/20 0.53
RARG P13631 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16622212 0.90 KMT2A (0.69) TDP1AOC3SMN1; SMN2HTTL3MBTL1
SCHEMBL7148287 0.84 SMN1; SMN2 (0.59) TDP1SMN1; SMN2HTTL3MBTL1TSHR
Actarit SCHEMBL1652616 0.82 KMT2A (0.61) TDP1SMN1; SMN2HTTL3MBTL1TSHR
Actarit SCHEMBL78305 0.82 KMT2A (0.61) TDP1SMN1; SMN2HTTL3MBTL1TSHR
SCHEMBL30779193 0.81 AOC3 (0.60) TDP1AOC3SMN1; SMN2HTTL3MBTL1
SCHEMBL11223377 0.81 CA2 (0.53) SMN1; SMN2KMT2ACA2MEN1
SCHEMBL28707343 0.81 KMT2A (0.56) TDP1SMN1; SMN2HTTL3MBTL1TSHR
SCHEMBL13514007 0.81 PTPN1 (0.56) TDP1SMN1; SMN2HTTL3MBTL1TSHR
SCHEMBL24819419 0.80 SMN1; SMN2 (0.73) TDP1SMN1; SMN2KMT2AALDH1A1MEN1
SCHEMBL1146000 0.80 SMN1; SMN2 (0.59) TDP1AOC3SMN1; SMN2HTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
WO-2023205188-A1 POTENT AND SELECTIVE HDAC6 MACROCYCLIC INHIBITORS UNIVERSITY OF WASHINGTON (US) 2023-10-26 WO disclosed
CN-109265451-A Butyrylcholinesterasselective selective inhibitors and preparation method thereof and purposes 中国药科大学 2019-01-25 CN disclosed
CN-108727307-A Compound and its application method 安吉奥斯医药品有限公司 2018-11-02 CN disclosed
CN-104936954-B Compounds and methods of use thereof 安吉奥斯医药品有限公司 2018-08-14 CN disclosed
EP-2922850-B1 COMPOUNDS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS INC (US) 2018-07-18 EP disclosed
CN-108069911-A 6- amino -2- phenyl pyrimidine classes compound, preparation method and medical usage 中国药科大学 2018-05-25 CN disclosed
CN-104936954-A compounds and methods of use thereof AGIOS PHARMACEUTICALS INC 2015-09-23 CN disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090042929-A1 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors STERIX LIMITED (GB) 2009-02-12 US disclosed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP disclosed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 TDP1 1051/4885AOC3 3866/4885SMN1; SMN2 3695/4885
US-20090042929-A1 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors HSD3B1, HSD3B2, HSD11B1 TDP1 3564/4885AOC3 1030/4885SMN1; SMN2 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.